吸入性糖皮质激素与COPD患者铜绿假单胞菌感染风险
随访期间763例(3.6%)获得铜绿假单胞菌,ICS使用与剂量依赖性风险升高相关,高剂量组风险最高。
要点
- COPD患者使用ICS与获得铜绿假单胞菌风险呈剂量依赖性升高。
- 高剂量ICS组风险最高(HR 3.58),临床对重症患者使用高剂量ICS需谨慎。
- 结果需在类似队列和其他环境中进一步验证。
核心结论
- 在丹麦门诊随访的COPD患者中,ICS使用与获得铜绿假单胞菌风险显著且剂量依赖性升高相关。
- 对重症COPD患者使用高剂量ICS时应谨慎。
- 上述结果需在可比队列和其他环境中确认。
研究设计与样本
- 多地区流行病学队列研究,纳入2010—2017年丹麦门诊随访的COPD患者。
- ICS使用按队列入组前365天累积处方取药情况分类。
- 采用Cox比例风险回归模型估计获得铜绿假单胞菌的风险。
- 采用倾向评分匹配模型作为敏感性分析。
主要发现
- 随访期间763例(3.6%)获得铜绿假单胞菌。
- 与未使用ICS相比,低剂量ICS组HR 1.38(95%CI 1.03至1.84,p=0.03)。
- 与未使用ICS相比,中剂量ICS组HR 2.16(95%CI 1.63至2.85,p<0.0001)。
- 与未使用ICS相比,高剂量ICS组HR 3.58(95%CI 2.75至4.65,p<0.0001)。
- 倾向匹配模型显示高剂量ICS相比无/低/中剂量ICS的HR 2.05(95%CI 1.76至2.39,p<0.0001)。
关键数值与推荐
- ICS使用与铜绿假单胞菌风险呈剂量依赖性:低剂量HR 1.38(95%CI 1.03至1.84,p=0.03)。
- 中剂量ICS:HR 2.16(95%CI 1.63至2.85,p<0.0001)。
- 高剂量ICS:HR 3.58(95%CI 2.75至4.65,p<0.0001)。
- 倾向匹配模型:高剂量相比无/低/中剂量ICS的HR 2.05(95%CI 1.76至2.39,p<0.0001)。
临床怎么用
- 对COPD患者处方ICS时应评估气道铜绿假单胞菌感染风险,尤其在高剂量使用时。
- 重症COPD患者使用高剂量ICS需谨慎。
- 可将累积ICS剂量作为铜绿假单胞菌感染风险的评估因素之一。
局限性
- 研究结果需在可比队列和其他环境中进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled corticosteroids (ICS) are commonly used to treat COPD and are associated with increased risk of pneumonia. The aim of this study was to assess if accumulated use of ICS is associated with a dose-dependent risk of a positive airway culture with Pseudomonas aeruginosa in patients with COPD. METHODS: We conducted a multiregional epidemiological cohort study including Danish COPD patients followed in outpatient clinics during 2010-2017. ICS use was categorised based on accumulated prescriptions redeemed 365 days prior to cohort entry. Cox proportional hazard regression model was used to estimate the risk of acquiring P. aeruginosa. Propensity score matched models were used as sensitivity analyses. RESULTS: A total of 21 408 patients were included in the study, of which 763 (3.6%) acquired P. aeruginosa during follow-up. ICS use was associated with a dose-dependent risk of P. aeruginosa (low ICS dose: HR 1.38, 95% CI 1.03 to 1.84, p=0.03; moderate ICS dose: HR 2.16, 95% CI 1.63 to 2.85, p<0.0001; high ICS dose: HR 3.58, 95% CI 2.75 to 4.65, p<0.0001; reference: no ICS use). A propensity matched model confirmed the results (high ICS dose compared with no/low/moderate ICS dose: HR 2.05, 95% CI 1.76 to 2.39, p p<0.0001). CONCLUSION: Use of ICS in patients with COPD followed in Danish outpatient clinics was associated with a substantially increased and dose-dependent risk of acquiring P. aeruginosa. Caution should be taken when administering high doses of ICS in severely ill patients with COPD. These results should be confirmed in comparable cohorts and other settings.
引用
- Eklöf J, Ingebrigtsen TS, Sørensen R, et al. Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Thorax. 2021. PMID: 34446524. doi:10.1136/thoraxjnl-2021-217160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。